Tax-driven share sale by SOPHiA GENETICS (SOPH) chief medical officer

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Medical Officer Philippe Menu sold 608 ordinary shares on March 19, 2026 in an open‑market transaction at a weighted average price of $4.7908 per share.

The footnotes state the sale was made to satisfy tax obligations from restricted stock units that vested on March 18, 2026 and was executed under a pre‑established Rule 10b5‑1 trading plan, meaning it was not a discretionary trade. Following the sale, Menu directly holds 173,616 shares.

Insider Trade Summary 10b5-1

Net Seller: 608 shares ($2,913)

Net Sell 1 txn

Insider Menu Philippe

Role Chief Medical Officer

Sold 608 shs ($3K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	608	$4.7908	$3K

Holdings After Transaction: Ordinary Shares — 173,616 shares (Direct)

Footnotes (1)

1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations arising in connection with the vesting of restricted stock units on March 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.73 to $4.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Menu Philippe

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/19/2026		S		608(1)	D	$4.7908(2)	173,616	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations arising in connection with the vesting of restricted stock units on March 18, 2026. These sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.73 to $4.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Philippe Menu	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did SOPHiA GENETICS (SOPH) report for Philippe Menu?

SOPHiA GENETICS reported that Chief Medical Officer Philippe Menu executed an open-market sale of 608 ordinary shares. The transaction occurred on March 19, 2026 and was linked to tax obligations from recently vested restricted stock units, according to the accompanying footnotes.

How many SOPHiA GENETICS (SOPH) shares did the CMO sell and at what price?

Philippe Menu sold 608 ordinary shares of SOPHiA GENETICS at a weighted average price of $4.7908 per share. Footnotes explain the shares were sold in multiple trades within a price range from $4.73 to $4.87, with full breakdown available upon request.

Why did SOPHiA GENETICS Chief Medical Officer sell shares in this Form 4 filing?

The sale was undertaken to satisfy tax obligations arising from the vesting of restricted stock units on March 18, 2026. Footnotes clarify that the transaction was tax-related rather than a discretionary decision to reduce investment exposure to SOPHiA GENETICS shares.

Was the SOPHiA GENETICS (SOPH) insider sale part of a Rule 10b5-1 trading plan?

Yes. The footnotes state the transactions were executed under a pre-established Rule 10b5-1 trading plan adopted by Philippe Menu. Such plans schedule trades in advance, so the timing of this sale is characterized as non-discretionary rather than an opportunistic market decision.

How many SOPHiA GENETICS shares does Philippe Menu hold after this reported sale?

After selling 608 ordinary shares, Philippe Menu directly holds 173,616 shares of SOPHiA GENETICS. This indicates the reported transaction involved only a small portion of his overall position, and the filing does not show any remaining derivative securities such as options or warrants.

What price range did SOPHiA GENETICS (SOPH) shares trade at in this insider sale?

The Form 4 notes that the reported weighted average price of $4.7908 reflects multiple trades executed between $4.73 and $4.87 per share. The reporting person has committed to provide detailed trade-by-trade pricing information upon written request to interested parties.